Reported Reactions

Reactions

MedDRA preferred term

Cardiac murmur: adverse event reports recording this term

8,477 reports to FDA record it, 2004–2026; 0% of the database.

8,477
reports recording the term
0% of all reports
252
reports, 12 months to June 2026
308 in the 12 months before
92.1%
marked serious by the reporter
57.4% across all reports
7.6%
record death among outcomes, as reported
9.1% across all reports

8,477 reports in FDA's adverse event database record the MedDRA term "Cardiac murmur": 0% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

252 reports recorded it in the 12 months to June 2026, down 18% from 308 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 92.1% are marked serious, 7.6% include death among the outcomes and 49.5% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Paxil, Fosamax and Humira. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

02753Jul 2021: 30Aug 2021: 30Sep 2021: 34Oct 2021: 17Nov 2021: 34Dec 2021: 252022Jan 2022: 10Feb 2022: 22Mar 2022: 44Apr 2022: 22May 2022: 28Jun 2022: 20Jul 2022: 19Aug 2022: 21Sep 2022: 22Oct 2022: 31Nov 2022: 35Dec 2022: 352023Jan 2023: 22Feb 2023: 18Mar 2023: 22Apr 2023: 42May 2023: 40Jun 2023: 20Jul 2023: 20Aug 2023: 12Sep 2023: 22Oct 2023: 16Nov 2023: 32Dec 2023: 152024Jan 2024: 32Feb 2024: 24Mar 2024: 16Apr 2024: 24May 2024: 25Jun 2024: 20Jul 2024: 24Aug 2024: 23Sep 2024: 31Oct 2024: 32Nov 2024: 26Dec 2024: 162025Jan 2025: 17Feb 2025: 53Mar 2025: 27Apr 2025: 18May 2025: 20Jun 2025: 21Jul 2025: 31Aug 2025: 22Sep 2025: 25Oct 2025: 25Nov 2025: 17Dec 2025: 132026Jan 2026: 20Feb 2026: 15Mar 2026: 26Apr 2026: 25May 2026: 14Jun 2026: 19

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

DrugClassReports with this termShare of the drug's own reports
PaxilSerotonin reuptake inhibitor7413.1%
FosamaxBisphosphonate4341.2%
Humira—4270.1%
PrednisoneCorticosteroid4110.2%
DigoxinCardiac glycoside3522.2%
Zofran—3014.2%
Vioxx—2890.7%
FurosemideLoop diuretic2820.6%
AcetaminophenNonsteroidal anti-inflammatory drug2720.3%
BudesonideCorticosteroid2251.5%
AspirinNonsteroidal anti-inflammatory drug2240.3%
Ipratropium bromideAnticholinergic1992.4%
Alendronate sodiumBisphosphonate1911.1%
Tiotropium bromideAnticholinergic1810.2%
SingulairLeukotriene receptor antagonist1800.9%
MetforminBiguanide1790.3%
Breo ElliptaCorticosteroid1700.8%
Zenhale—1636.8%
OmeprazoleProton pump inhibitor1610.3%
MesalamineAminosalicylate1601.8%
GabapentinAnti-epileptic agent1590.2%
NasonexCorticosteroid1582.9%
SulfasalazineAminosalicylate1560.4%
InfliximabTumor necrosis factor blocker1550.3%
FelodipineDihydropyridine calcium channel blocker1547.5%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

ClassReports with this termShare of class reportsMedian drug in class
Corticosteroid1,6670.2%0%
Serotonin reuptake inhibitor1,2650.5%0.1%
Anticholinergic7380.5%0%
Bisphosphonate6580.7%0.1%
Tumor necrosis factor blocker6120.1%0%
Nonsteroidal anti-inflammatory drug6070.1%0%
Atypical antipsychotic6040.1%0%
Proton pump inhibitor5260.1%0%
Anti-epileptic agent4290.2%0%
Cardiac glycoside3542.1%1.2%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 25.5%468
2 to 111.7%143
12 to 171.1%97
18 to 448.1%689
45 to 6418.3%1,551
65 to 7410.4%880
75 and over11.3%959
Age not given43.5%3,690

Patient sex

Female56.1%4,758
Male35.9%3,040
Not given8%679

Grey bar: all 20,646,523 reports in the database. 63.5% of these reports give the United States as the country.

Questions about "Cardiac murmur"

What does "Cardiac murmur" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record cardiac murmur?

8,477 reports through June 2026 (0% of all reports), 252 of them in the latest 12 months.

Which drugs appear most often in these reports?

Paxil (741), Fosamax (434), Humira (427), Prednisone (411) and Digoxin (352). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.